Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions

Nicola Ferri, Elisa Colombo, Alberto Corsini

Open source

DOI
10.3390/pharmaceutics16111371
Published
2024-10-26
Container
Pharmaceutics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics16111371,
  title = {Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions},
  author = {Nicola Ferri and Elisa Colombo and Alberto Corsini},
  year = {2024},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics16111371},
  url = {https://doi.org/10.3390/pharmaceutics16111371}
}

RIS

TY  - JOUR
TI  - Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
AU  - Nicola Ferri
AU  - Elisa Colombo
AU  - Alberto Corsini
PY  - 2024
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics16111371
UR  - https://doi.org/10.3390/pharmaceutics16111371
ER  - 

APA

Ferri, N., Colombo, E., & Corsini, A. (2024). Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions. Pharmaceutics. https://doi.org/10.3390/pharmaceutics16111371

Source records